Overview of MS Contin

Property	Description
Active ingredient	Morphine Sulfate
Form	Extended-release tablet (Controlled-release oral formulation)
Pharmacological class	Opioid Analgesic
General purpose	Sustained management of persistent pain
Origin	Derived from Opium alkaloid (Natural product)

What is MS Contin and What is its Composition?

MS Contin is a recognized brand name for a potent medicinal preparation classified as an opioid analgesic, containing Morphine Sulfate as its sole active ingredient. The active substance is an opium alkaloid, meaning the compound is naturally derived from the opium poppy, belonging to the Phenanthrene chemical class. Morphine acts as an agonist at the mu-opioid receptor, which is responsible for its analgesic effects. This confirmed mechanism shows the medicine reduces discomfort by modifying key pain signaling pathways in the central nervous system.

The drug entity acts as a powerful opioid agonist that primarily functions within the central nervous system. As a single-entity product, MS Contin contains only this established pain-relieving compound, a feature that is pharmacologically recognized for simplifying dosage adjustment when compared to combination products. Its identity as a time-tested substance ensures direct, powerful analgesic action utilized in continuous pain management protocols.

What is an Extended-Release Morphine Tablet?

MS Contin is an oral formulation presented as an extended-release tablet, a specialized form engineered to dissolve slowly and continuously after ingestion. This designation, often abbreviated as CR (controlled-release), is the distinguishing feature of this brand and signifies the tablet's unique pharmaceutical design, which carefully controls the rate at which the Morphine Sulfate is absorbed into the bloodstream.

The extended-release form is functionally distinct from immediate-release tablets, which are designed to deliver medication rapidly. Instead, the CR mechanism utilizes a solid matrix of pharmaceutical excipients to meter the drug delivery over many hours. The principal benefit of these extended-release opioid formulations is providing smooth, steady blood concentrations. This design feature ensures a stable, consistent level of the drug, which is essential for managing continuous pain.

General Purpose: Sustained Relief for Moderate to Severe Pain

The general purpose of MS Contin is to provide continuous, around-the-clock analgesia for managing persistent, chronic pain states. This continuous application is clinically recognized as the standard approach for managing background pain in oncology and non-terminal conditions. By combining a potent opioid analgesic with controlled-release technology, the medication is engineered to sustain a therapeutic effect without interruption. This capability means the drug is intended for patients whose discomfort requires reliable management of moderate to severe pain that persists throughout the day and night. Its sustained action is essential for maintaining baseline comfort and functional stability.

Regulatory References

What side effects are possible with MS Contin?

Possible Side Effects and Safety Information

The safety profile of MS Contin, an extended-release morphine sulfate formulation, is officially defined by its frequency-classified adverse reactions and serious safety constraints documented by government regulatory authorities.

Adverse Reaction Classification

Side effects are categorized by frequency and the body system affected (System-Organ Class or SOC). Based on regulatory documentation, the most frequently reported effects include:

Frequency	Adverse Reaction (Selection)
Very Common (≥1/10)	Constipation, Nausea
Common (≥1/100 to <1/10)	Vomiting, Somnolence (Sedation), Dizziness, Pruritus (Itching)
Not Known	Respiratory depression, Drug Dependence, Hyperalgesia, Allodynia

The most commonly affected systems include Gastrointestinal Disorders and Nervous System Disorders.

Serious Adverse Reactions and Safety Constraints

The official labeling highlights several serious and potentially life-threatening risks. The primary safety concern is Respiratory Depression, which is cited as a serious, life-threatening, or fatal risk. The risk is documented as highest upon the initiation of therapy or following a dose increase.

Regulatory documents also detail the risks of Opioid Dependence, Abuse, and Misuse. Furthermore, the ingestion of even a single tablet by a person not accustomed to opioids can result in a fatal overdose. Specific cautions apply to patients with renal or hepatic impairment, and the elderly are explicitly noted to be at an increased risk of respiratory depression. Long-term use is associated with risks like tolerance and adrenal insufficiency. Concurrent use with other CNS depressants is constrained due to the risk of profound sedation, coma, and death.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define an overdose of Morphine Sulfate extended-release as a severe, life-threatening event requiring immediate medical intervention. Overdose is characterized by acute toxicity related to profound central nervous system (CNS) depression.

Documented Manifestations and Severe Outcomes

Manifestations of overdose include deep stupor, somnolence, or coma (inability to be awakened). Observable physical signs documented in official labeling include extremely small pupils (miosis), skeletal muscle flaccidity, and cold, clammy skin. The most serious and potentially fatal outcome is life-threatening respiratory depression, which can quickly progress to respiratory arrest, circulatory collapse, and ultimately, death. Accidental ingestion of even a single tablet, particularly by a child, is considered a medical emergency with the potential for a fatal overdose.

Required Emergency Action

Immediate medical attention must be sought if any signs of overdose are suspected, such as slowed or stopped breathing, unresponsiveness, or bluish lips/fingernails. Emergency services must be contacted without delay. Naloxone is documented as the specific opioid antagonist available to reverse the effects. Management procedures include establishing and maintaining a patent airway, providing supportive care, and ensuring continuous hospital monitoring due to the prolonged effect of the extended-release formulation. Official labeling notes an increased risk of severe respiratory depression in elderly and debilitated patients or those with renal/hepatic impairment.

Therapeutic Uses of MS Contin

The primary purpose of MS Contin is to provide continuous, around-the-clock support that contributes to easing the overall symptom burden for managing persistent, chronic pain states. This extended-release formulation is intended for managing symptoms related to physical discomfort that requires steady, long-term coverage. The medicine is generally applied for managing pain severe enough to require daily, long-term opioid treatment when alternative options are inadequate.

Sustained Management of Severe Chronic Pain

This medication is commonly used across conditions presenting with severe, chronic pain, including intractable pain syndromes and cancer pain. It is typically applied in situations where the severity of the symptoms creates noticeable functional strain. The key benefit is that it helps provide continuous symptom relief, which assists with maintaining functional stability and supports general well-being during symptomatic phases.

Symptom Control in Palliative and Advanced Care

MS Contin is considered relevant to specialty care focused on symptomatic support, including palliative care. It also plays a role in managing severe, chronic breathlessness (dyspnea) in specific advanced care settings. This therapeutic role supports patients during difficult episodes by easing distress, helping them cope more steadily, and contributing to improved day-to-day comfort.

Quick Fact: Therapeutic Scope for Persistent, Severe Pain

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory information restricts MS Contin (morphine sulfate extended-release) for use in patients with severe, continuous pain that requires daily, around-the-clock, long-term opioid treatment. The drug is contraindicated for use as an as-needed (prn) analgesic or for managing mild or acute pain.

Contraindicated Populations	Restricted/Conditional Use
Significant respiratory depression	Impaired renal or hepatic function (requires caution)
Acute or severe asthma	Elderly or debilitated patients (risk of respiratory depression)
Known or suspected paralytic ileus or GI obstruction	Increased intracranial pressure or head injury (monitor closely)
Concurrent use of MAO inhibitors	Pregnancy (risk of Fetal Harm, Neonatal Opioid Withdrawal Syndrome)

For pediatric patients (under 18), safety and effectiveness are not established in U.S. regulatory labeling. Additionally, the highest dose tablets (100 mg and 200 mg) are reserved only for patients in whom opioid tolerance has been formally established.

What should I know about interactions with other medicines?

The interaction profile for MS Contin (Morphine Sulfate extended-release) is strictly defined by formal patterns documented in government regulatory sources. Co-administration is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including use within 14 days of discontinuing an MAOI, due to the risk of severe central nervous system (CNS) instability. Use is also contraindicated in the presence of known or suspected gastrointestinal obstruction.

Clinically significant pharmacodynamic interactions involve substances that augment CNS depression. Combining the medicine with CNS depressants such as benzodiazepines, sedatives, hypnotics, or alcohol can result in severe sedation, respiratory depression, and coma. Co-use with Serotonergic Drugs carries the documented risk of serotonin syndrome. Additionally, co-administration with Mixed Agonist/Antagonist Opioids is advised to be avoided as it may reduce the analgesic effect or precipitate withdrawal.

Pharmacokinetic interactions involve the systemic exposure of morphine. The drug is classified as a substrate for P-glycoprotein (P-gp); therefore, P-gp inhibitors can increase morphine plasma concentrations. The metabolic inhibitor Cimetidine is documented to potentiate effects by inhibiting metabolism. A timing rule requires that the medicine must be administered at least two hours apart from antacids due to the risk of altering the drug's extended-release mechanism. These interaction risks may be heightened in populations with severe hepatic or renal impairment.

Mechanism of Action

The mechanism of MS Contin (Morphine Sulfate) centers on its action within the central nervous system (CNS) to modulate the transmission of nociceptive signals.

Targeted Agonism and Cellular Inhibition

The drug functions as a full agonist at the mu-opioid receptor (mu-OR), the principal molecular target located on nerve cells in the spinal cord and brainstem. This binding initiates a G-protein coupled cascade via G i/ G o proteins. This sequence causes the opening of specific potassium channels ( K^+ efflux), promoting neuronal hyperpolarization, and the closure of voltage-gated calcium channels ( Ca^2+ influx prevention). This dual cellular action inhibits neuronal excitability and reduces the presynaptic release of excitatory neurotransmitters involved in nociception.

Modulating Central Nociceptive Pathways

The resulting inhibition translates into a system-level effect by modulating signal propagation across the neural network. Morphine's action reduces signal flow in the ascending nociceptive pathways that transmit input from the spinal cord to the brain, while concurrently activating the brain's intrinsic descending inhibitory pathways. This integrated modulation of the nociceptive network produces a physiological effect that modifies the central processing of nociceptive input.

Dosage and Administration Information

How MS Contin is Used

MS Contin is an extended-release formulation of Morphine Sulfate and is administered exclusively by the oral route for continuous, around-the-clock pain management. The extended-release design requires the medicine to be used on a fixed, scheduled basis and is not intended for as-needed (PRN) use.

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral (swallowing the tablet).
Dosing Schedule	Fixed schedule, typically every 8 hours or every 12 hours.
Timing in Relation to Meals	May be taken with or without food.

Dosage Principles and Procedural Constraints

The dosage for MS Contin is individually determined through titration. For patients who have not previously taken opioids (opioid-naïve), treatment is typically initiated with a low dose, such as 15 mg. Higher strengths, including the 100 mg and 200 mg tablets, are restricted to patients who meet the clinical definition of being opioid-tolerant.

To ensure proper function of the extended-release mechanism, the tablets must be swallowed whole and must not be cut, crushed, dissolved, or chewed. Dosage adjustments (titration) may be implemented every 1 to 2 days as needed. For older adults and patients with liver or kidney impairment, a reduced initial dose and cautious titration are generally advised.

Recent Clinical Evidence

Research Evidence / Overview of Studies for MS Contin

Evidence for Use in Severe Chronic Cancer Pain

Extended-release morphine was studied for its role in examining persistent, around-the-clock outcomes related to physical discomfort in patients with severe pain due to cancer. Research includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that monitored short-term symptom patterns. These studies compare the controlled-release formulation with immediate-release versions.

Researchers monitored outcomes such as pain intensity scores and patient-reported measures of perceived discomfort to observe how symptoms evolved in the observed populations. Research in this area describes a clear structure of research for evaluating pain in conditions marked by functional limitations. Despite the long history of use, research highlights that many individual trials sample sizes were modest, and evidence quality varies across studies due to different methods used to measure outcomes.

Evidence for Use in Severe Chronic Non-Cancer Pain

Extended-release morphine was evaluated in studies involving adults with conditions where symptoms may vary in intensity, such as severe chronic back pain and osteoarthritis. Research designs included standard RCTs and specialized Enriched Enrollment Randomized Withdrawal (EERW) studies.

Studies explored outcomes reflecting daily functioning or activity level, alongside patient-reported outcomes describing pain intensity. Systematic reviews covering these areas report how symptoms evolved in the observed populations, and findings indicate that the differences measured between the treatment group and placebo group were often small in magnitude in short-term trials.

Research Gaps and Areas of Uncertainty

The evidence for this indication is limited in several ways. Follow-up durations in the most rigorous controlled studies were limited to short-term intervals. Furthermore, there is limited information for long-term outcomes to fully describe stability in long-term follow-up. Research also highlights that there is no high-quality evidence for the efficacy of very high-dose regimens (e.g., doses equivalent to 200 mg or more daily) in the CNCP population.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about MS Contin (FAQ)

Q: How long does the pain-relief effect of MS Contin typically last?

MS Contin is designed as an extended-release formulation intended for continuous pain management. Official prescribing information indicates that the medicine is administered on a fixed schedule, typically every 8 or every 12 hours, to provide sustained relief.

Q: Are there any specific foods or drinks to avoid while taking MS Contin?

Yes, official warnings strongly advise against the co-administration of alcohol with this medicine, as the combination carries the risk of severe sedation and breathing problems. Additionally, regulatory information states that antacids should be taken at least two hours apart from the medication to avoid potentially altering its extended-release mechanism.

Q: How quickly does MS Contin start working after taking a dose?

Because MS Contin is an extended-release tablet, it is formulated for a gradual and slow release of the active ingredient. Official documents note that the maximum risk for respiratory depression occurs within the first few days of starting treatment, which suggests when the drug concentration is stabilizing.

Q: Are warnings provided about combining MS Contin with alcohol?

Yes, regulatory documentation includes a Boxed Warning that explicitly details the serious risks of combining the medicine with alcohol. These documented risks include severe sedation, coma, and potentially fatal respiratory depression (slowed breathing).

Q: What is the difference between MS Contin and Kadian, which is also an extended-release morphine?

Both MS Contin and Kadian are brand names for extended-release formulations of morphine sulfate. Regulatory bodies like the FDA classify generic versions of both products and evaluate them to determine acceptable bioequivalence to the respective reference listed drug.

Q: Is MS Contin used for chronic pain only, or for severe short-term pain too?

According to official documentation, this medicine is indicated for managing pain that requires continuous, around-the-clock opioid treatment over an extended period. It is not intended for use as an as-needed analgesic, or for managing mild or acute (short-term) pain.

Q: Is it possible to become tolerant to the effects of MS Contin over time?

Official safety information documents that tolerance to the medicine is a risk, meaning that over time, a higher dose may be required to achieve a similar level of effect. Furthermore, long-term use is associated with a risk of conditions like adrenal insufficiency.

Q: Does MS Contin affect the ability to drive or operate machinery?

Regulatory labeling indicates the medicine can cause side effects like dizziness and somnolence (sedation), which are documented to impair alertness and coordination. Patients are generally advised not to drive or operate machinery until the effects on them have been determined.

Q: Can MS Contin be used by people with kidney problems?

Official prescribing information states that the medicine requires caution for patients with impaired renal (kidney) function. This is due to the potential for increased risk of adverse reactions, including breathing problems. A reduced initial dose and careful management are often advised in this population.

Q: Are there any known interactions between MS Contin and herbal supplements?

Official interaction sections focus primarily on prescription drug classes, particularly those that increase CNS depression (sedation). Patients are generally advised in the prescribing information to inform their healthcare professional of all concomitant drugs, including any herbal or vitamin supplements.

Q: Does MS Contin appear in standard drug screening tests?

The active ingredient in this medicine is morphine, which belongs to the opioid class of analgesics. Morphine can be detected in many standard drug screening tests.

Q: Are the generic versions of MS Contin considered equivalent to the brand name?

Yes, the FDA has approved generic versions of this medicine. Products with an AB rating in the FDA's Orange Book are considered by regulatory bodies to have demonstrated acceptable bioequivalence to the reference listed drug.

Q: What are some signs that a person might be taking more MS Contin than intended?

Signs of taking more medicine than intended often involve symptoms of severe respiratory or central nervous system (CNS) depression. These may include shallow or slowed breathing, extreme sleepiness, or becoming unresponsive.

Q: Can older adults use MS Contin, and are there special considerations for them?

Older adults can use the medicine, but they are generally noted in official information to be at an increased risk for adverse effects like respiratory depression. For this reason, a reduced initial dose and careful monitoring are often advised for this population.

Q: What is the general relationship between MS Contin and sleep patterns?

The medicine is a central nervous system (CNS) depressant and lists somnolence (sedation) as a common side effect. This documented sedative effect may influence or alter typical sleep patterns.

Q: Is there any information on how long MS Contin stays in the body after the last dose?

Studies on the drug's activity indicate that the main active ingredient, morphine, has a documented terminal half-life of approximately 2 to 4 hours. This time frame suggests how quickly the amount of medicine in the body is reduced by half.

Q: Are certain types of headaches listed as side effects of MS Contin?

While headaches are not consistently listed among the most frequently reported adverse reactions, official documentation has referenced the occurrence of headache as a less common side effect.

Q: Does MS Contin interact with common over-the-counter cold and flu medicines?

Interactions are documented for medicines that are Central Nervous System (CNS) depressants, which can include certain components in over-the-counter cold and flu products like some antihistamines. Combining these medicines may increase the risk of sedation and serious breathing problems.

Q: Can MS Contin cause changes in mood or emotional state?

As a central nervous system depressant, the use of this medicine can affect emotional state. Official documents have linked its use, particularly during dose reduction or discontinuation, to symptoms such as anxiety, irritability, and changes in mood.

Q: Is there a link between the use of MS Contin and hormone levels?

Yes, official labeling notes that the long-term use of opioids, including this medicine, has been associated with a potential risk of adrenal insufficiency. This is a condition where the adrenal glands, which help regulate hormone levels, may not produce enough of the hormone cortisol.

Q: What is the intended duration of use for MS Contin in typical treatment plans?

The medicine is specifically indicated for managing pain that requires treatment for an extended period of time on a continuous basis. It is not intended for short-term or temporary pain relief.

Q: How does the extended-release feature of MS Contin differ from continuous pain relief?

The extended-release feature is the specific pharmaceutical mechanism—the slow, steady release of the medicine—that enables the intended continuous, around-the-clock pain relief. This design is essential for maintaining a stable level of the drug for baseline comfort.

Q: Are there specific patient populations where research on MS Contin is limited?

Yes, official regulatory labeling indicates that the safety and effectiveness for pediatric patients (under 18) are not established in the U.S. Furthermore, research often highlights limitations in the duration of follow-up for studies involving chronic non-cancer pain.

Q: Does using MS Contin increase the risk of developing pain sensitivity (hyperalgesia)?

Official safety information documents the risk of Opioid-Induced Hyperalgesia and Allodynia. Hyperalgesia means increased sensitivity to pain, and Allodynia is feeling pain from a non-painful stimulus.

Q: What precautions are described for patients with pre-existing breathing problems taking MS Contin?

The medicine is contraindicated (should not be used) in patients with acute or severe bronchial asthma. For patients with chronic breathing conditions, official documents advise caution due to the documented risk of severe or fatal respiratory depression (slowed breathing).

Q: Is MS Contin used to treat non-cancer-related chronic pain?

The medicine is indicated for severe pain that requires a continuous opioid analgesic. Clinical studies and research summaries have evaluated the medicine for use in various types of severe pain, including chronic non-cancer pain.

Q: Are dizziness or drowsiness common side effects when starting MS Contin?

Official documents list both dizziness and somnolence (sedation) as common adverse reactions. Common adverse reactions are those reported in at least 1 out of every 100 patients.

Q: Is there a risk of interaction between MS Contin and antidepressant medications?

Yes, the co-administration of this medicine with Serotonergic Drugs, which include many types of antidepressants, carries a documented risk of serotonin syndrome. This is a potentially serious condition involving high levels of serotonin in the body.

Q: Why are people often confused about the difference between dependence and addiction with MS Contin?

Regulatory documents explicitly address the risks of Addiction, Abuse, and Misuse, as well as the presence of physical dependence. The risks of these related, but distinct, conditions are highlighted together in the safety constraints, which may contribute to general confusion.

How should MS Contin be stored and disposed of?

Storage and Disposal Instructions for MS CONTIN

MS CONTIN (morphine sulfate extended-release) must be stored under specific regulatory conditions to maintain stability and prevent accidental ingestion.

Required Storage Conditions

The tablets must be stored at room temperature, specifically below 25 C. The medicine must be protected from light and moisture, and it must not freeze. It is mandatory to keep the tablets in a closed container and securely out of the sight and reach of children at all times to prevent fatal overdose.

Official Disposal Requirements

Unused or expired tablets should be disposed of by taking them to a DEA-authorized take-back program. If a take-back option is not readily available, the FDA advises that the tablets be immediately flushed down the toilet to eliminate the risk of accidental exposure. Disposal must be conducted according to local regulations.

MS Contin